focus -WSS

focus

author：fashion 2025-09-30 23:39:34 - browse：3282

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Excited delirium, Elijah McClain, and emergency physicians

WSS

STAT Executive Editor Rick Berke on STAT's 8th birthday

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Doctors in states that ban abortion can still help patients

UCSF medical school apologizes for unethical prisoner experiments

Doctors in states that ban abortion can still help patients

A clever new way to fix Medicaid and graduate medical education

hotspot

focus

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Adidas to release second batch of Yeezy sneakers after breakup with Ye

Moonlake's readout produced a cash windfall. Risks remain

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

After affirmative action ruling, medical educators look to 'holistic review'

What AstraZeneca

Medicare proposal to cover medical devices draws a mixed reaction

STAT Executive Editor Rick Berke on STAT's 8th birthday

After affirmative action ruling, medical educators look to 'holistic review'

Adidas to release second batch of Yeezy sneakers after breakup with Ye

explore

Removing probiotics from the NICU could threaten preemies' health

FDA approves potent Eli Lilly obesity drug, Zepbound

Sanofi CEO defends move to abandon profit guidance, boost research

Diversify hospital leadership teams to protect BIPOC patient health

HCA says smaller share of spending going to labor

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

hotspot

focus

hotspot

leisure time